Cyclin G2, a novel target of sulindac to inhibit cell cycle progression in colorectal cancer

Hongyou Zhao; Bin Yi; Zhipin Liang; Ches’Nique Phillips; Hui-Yi Lin; Adam I. Riker; Yaguang Xi

doi:10.1016/j.gendis.2020.11.006

您当前的位置：

首页 >

文章列表页 >

Cyclin G2, a novel target of sulindac to inhibit cell cycle progression in colorectal cancer

Full-length article | 更新时间：2022-06-24

- Cyclin G2, a novel target of sulindac to inhibit cell cycle progression in colorectal cancer
- Cyclin G2, a novel target of sulindac to inhibit cell cycle progression in colorectal cancer
- Genes & Diseases 2021年8卷第3期
- 作者机构：
  
  1. Department of Genetics and Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center,New Orleans,USA,70112
  2. School of Public Health, Louisiana State University Health Sciences Center,New Orleans,USA,70112
  3. Geaton and JoAnn DeCesaris Cancer Institute, Anne Arundel Medical Center, Luminis Health, Annapolis,MD,USA,21401
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2020.11.006
  中图分类号：
- 纸质出版日期：2021，
  
  网络出版日期：2021-5-1，
扫描看全文
Hongyou Zhao, Bin Yi, Zhipin Liang, 等. Cyclin G2, a novel target of sulindac to inhibit cell cycle progression in colorectal cancer[J]. Genes & Diseases, 2021,8(3).

Hongyou Zhao, Bin Yi, Zhipin Liang, et al. Cyclin G2, a novel target of sulindac to inhibit cell cycle progression in colorectal cancer[J]. Genes & Diseases, 2021,8(3).
Hongyou Zhao, Bin Yi, Zhipin Liang, 等. Cyclin G2, a novel target of sulindac to inhibit cell cycle progression in colorectal cancer[J]. Genes & Diseases, 2021,8(3). DOI： 10.1016/j.gendis.2020.11.006.

Hongyou Zhao, Bin Yi, Zhipin Liang, et al. Cyclin G2, a novel target of sulindac to inhibit cell cycle progression in colorectal cancer[J]. Genes & Diseases, 2021,8(3). DOI： 10.1016/j.gendis.2020.11.006.

摘要

Abstract

Sulindac has shown significant clinical benefit in preventing colorectal cancer progression

but its mechanism of action has not been fully elucidated. We have found that sulindac sulfide (SS) is able to inhibit cell cycle progression in human colorectal cancer cells

particularly through G1 arrest. To understand the underlying mechanisms of sulindac inhibitory activity

we have demonstrated that Cyclin G2 up-regulation upon SS treatment can substantially delay cell cycle progression by enhancing the transcriptional activity of FOXO3a in human colorectal tumor cells. MiR-182

an oncogenic microRNA known to inhibit FOXO3a gene expression

is also involved in the suppressive effect of SS on cell cycle progression. This process begins with the down-regulation of miR-182

followed by the enhancement of FOXO3a transcriptional activity and the up-regulation of Cyclin G2. To further determine the clinical utility of this axis

we analyzed the expression of miR-182/FOXO3a/Cyclin G2 in human colorectal tumor samples. Our results show not only that there are significant differences in miR-182/FOXO3a/Cyclin G2 between tumors and normal tissues

but also that the synergetic effect of miR-182 and FOXO3a is associated with predicting tumor progression. Our study demonstrates a novel mechanistic axis consisting of miR-182/FOXO3a/Cyclin G2 that mediates sulindac inhibition of cell cycle progression.

关键词

Keywords

Cell cycleColorectal cancerGene regulationmiRNASulindac

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

Is there a potential of circulating miRNAs as biomarkers in rheumatic diseases?

Interplays of liver fibrosis-associated microRNAs: Molecular mechanisms and implications in diagnosis and therapy

Functions and mechanisms of protein lysine butyrylation (Kbu): Therapeutic implications in human diseases

A novel aptamer-based small RNA delivery platform and its application to cancer therapy

Cell cycle dysregulation with overexpression of KIF2C/MCAK is a critical event in nasopharyngeal carcinoma